Nykredit A S Takes $10.30 Million Position in IQVIA Holdings Inc. $IQV

Key Points

• Nykredit A S acquired 53,299 IQVIA shares during the second quarter, valued at approximately $10.3 million. Institutional investors collectively own 89.62% of the company.
• IQVIA reported quarterly earnings of $3.15 per share and revenue of $4.37 billion, exceeding analyst expectations; revenue increased 8.7% year over year.
• Analysts remain broadly positive, with a consensus rating of “Moderate Buy” and an average price target of $248, while several firms recently raised their targets. Shares opened at $266.69, near the company’s 52-week high.

Nykredit A S purchased a new position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 53,299 shares of the medical research company's stock, valued at approximately $10,298,000.

Other institutional investors have also bought and sold shares of the company. BlackRock Inc. purchased a new position in shares of IQVIA during the 2nd quarter valued at $2,811,292,000. Geode Capital Management LLC increased its holdings in IQVIA by 0.6% in the 4th quarter. Geode Capital Management LLC now owns 4,374,971 shares of the medical research company's stock worth $982,272,000 after acquiring an additional 24,453 shares during the last quarter. Boston Partners raised its stake in IQVIA by 14.9% in the 4th quarter. Boston Partners now owns 4,087,380 shares of the medical research company's stock valued at $923,276,000 after acquiring an additional 530,672 shares during the period. JPMorgan Chase & Co. lifted its holdings in IQVIA by 16.2% during the fourth quarter. JPMorgan Chase & Co. now owns 3,799,600 shares of the medical research company's stock valued at $856,468,000 after purchasing an additional 528,753 shares during the last quarter. Finally, Norges Bank bought a new position in IQVIA during the fourth quarter worth about $497,445,000. Hedge funds and other institutional investors own 89.62% of the company's stock.

IQVIA Stock Up 0.1%

Shares of NYSE:IQV opened at $266.69 on Monday. The firm has a fifty day moving average price of $242.66 and a two-hundred day moving average price of $199.61. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.71 and a quick ratio of 0.71. IQVIA Holdings Inc. has a one year low of $154.50 and a one year high of $273.88. The company has a market cap of $43.90 billion, a price-to-earnings ratio of 33.09, a PEG ratio of 2.28 and a beta of 1.18.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, topping the consensus estimate of $3.03 by $0.12. The firm had revenue of $4.37 billion for the quarter, compared to analysts' expectations of $4.30 billion. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The business's quarterly revenue was up 8.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.81 earnings per share. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Analysts anticipate that IQVIA Holdings Inc. will post 11.56 EPS for the current fiscal year.

Analyst Ratings Changes

IQV has been the topic of several research reports. Barclays reissued an "overweight" rating on shares of IQVIA in a research report on Tuesday, July 28th. JPMorgan Chase & Co. lifted their price objective on shares of IQVIA from $225.00 to $285.00 and gave the company an "overweight" rating in a research note on Wednesday, July 29th. Stifel Nicolaus boosted their target price on shares of IQVIA from $220.00 to $276.00 and gave the company a "buy" rating in a report on Wednesday, July 29th. Weiss Ratings upgraded IQVIA from a "hold (c-)" rating to a "hold (c)" rating in a research report on Wednesday, July 15th. Finally, Morgan Stanley raised their price target on IQVIA from $240.00 to $270.00 and gave the stock an "equal weight" rating in a report on Thursday. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $248.00.

Insider Transactions at IQVIA

In related news, insider Bhavik Patel sold 1,855 shares of the company's stock in a transaction that occurred on Friday, July 31st. The shares were sold at an average price of $235.27, for a total value of $436,425.85. Following the transaction, the insider directly owned 1,348 shares in the company, valued at approximately $317,143.96. This represents a 57.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Eric Sherbet sold 5,000 shares of the firm's stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $249.16, for a total transaction of $1,245,800.00. Following the completion of the sale, the insider directly owned 20,999 shares in the company, valued at $5,232,110.84. This represents a 19.23% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 15,581 shares of company stock worth $3,796,021. 1.70% of the stock is owned by insiders.

About IQVIA

IQVIA Holdings Inc is a global provider of advanced analytics, technology solutions and contract research services for the life sciences industry. The company supports pharmaceutical, biotechnology and medical device companies throughout the product life cycle, from research and clinical development through commercialization and post-market activities.

Its offerings include clinical trial management, site and patient services, real-world evidence, healthcare data, regulatory and safety services, commercial analytics, consulting, and technology platforms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.